We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
- Authors
Mesplède, Thibault; Wainberg, Mark A.
- Abstract
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.
- Subjects
INTEGRASE inhibitors; DRUG resistance; HIV infections; THERAPEUTICS; DRUG approval; ANTIRETROVIRAL agents; UNITED States. Food &; Drug Administration
- Publication
Viruses (1999-4915), 2014, Vol 6, Issue 9, p3377
- ISSN
1999-4915
- Publication type
Article
- DOI
10.3390/v6093377